Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18108506 | 0.77 | TSHR (0.35) | ESR1ESR2TSHRLMNAALDH1A1 | |
| SCHEMBL18108202 | 0.77 | ESR1 (0.44) | ESR1ESR2NR1H2NR1H3MAPT | |
| SCHEMBL68909 | 0.77 | ESR1 (0.44) | ESR1ESR2NR1H2NR1H3MAPT | |
| SCHEMBL197544 | 0.77 | ESR1 (0.44) | ESR1ESR2NR1H2NR1H3MAPT | |
| SCHEMBL144807 | 0.77 | ESR1 (0.44) | ESR1ESR2NR1H2NR1H3MAPT | |
| SCHEMBL9383203 | 0.77 | ESR1 (0.44) | ESR1ESR2NR1H2NR1H3MAPT | |
| SCHEMBL8967403 | 0.77 | ESR1 (0.44) | ESR1ESR2NR1H2NR1H3MAPT | |
| SCHEMBL18108392 | 0.77 | TSHR (0.35) | ESR1ESR2TSHRLMNAALDH1A1 | |
| SCHEMBL7665890 | 0.77 | ESR1 (0.44) | ESR1ESR2NR1H2NR1H3MAPT | |
| SCHEMBL18108106 | 0.77 | TSHR (0.35) | ESR1ESR2TSHRLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768733-A1 | SILICON-TERMINATED TELECHELIC POLYOLEFIN COMPOSITIONS AND PROCESSES FOR PREPARING THE SAME | Dow Global Technologies LLC (US) | 2021-01-27 | — | — | EP | disclosed |
| EP-3768732-A1 | PROCESS FOR FUNCTIONALIZATION OF ORGANO-ZINC COMPOUNDS WITH HALOSILANES USING BASIC NITROGEN CONTAINING HETEROCYCLES AND SILYL-FUNCTIONALIZED COMPOUNDS PREPARED THEREBY | Dow Global Technologies LLC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20210017195-A1 | PROCESS FOR FUNCTIONALIZATION OF ORGANO-ZINC COMPOUNDS WITH HALOSILANES USING BASIC NITROGEN CONTAINING HETEROCYCLES AND SILYL-FUNCTIONALIZED COMPOUNDS PREPARED THEREBY | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-01-21 | — | — | US | disclosed |
| US-20210017311-A1 | SILICON-TERMINATED TELECHELIC POLYOLEFIN COMPOSITIONS AND PROCESSES FOR PREPARING THE SAME | DOW GLOBAL TECHNOLOGIES LLC | 2021-01-21 | — | — | US | disclosed |
| CN-111868110-A | Silicon-terminated telechelic polyolefin compositions and methods of making the same | 陶氏环球技术有限责任公司 | 2020-10-30 | — | — | CN | disclosed |
| CN-111868109-A | Method for functionalizing organozinc compounds with halosilanes using basic nitrogen-containing heterocycles and silane-functionalized compounds prepared therefrom | 陶氏环球技术有限责任公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2019182992-A1 | PROCESS FOR FUNCTIONALIZATION OF ORGANO-ZINC COMPOUNDS WITH HALOSILANES USING BASIC NITROGEN CONTAINING HETEROCYCLES AND SILYL-FUNCTIONALIZED COMPOUNDS PREPARED THEREBY | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019182993-A1 | SILICON-TERMINATED TELECHELIC POLYOLEFIN COMPOSITIONS AND PROCESSES FOR PREPARING THE SAME | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-09-26 | — | — | WO | disclosed |
| US-9884928-B2 | Polymers functionalized with activated nitrogen heterocycles containing a pendant functional group | BRIDGESTONE CORPORATION (JP) | 2018-02-06 | — | — | US | disclosed |
| US-20160289354-A1 | POLYMERS FUNCTIONALIZED WITH ACTIVATED NITROGEN HETEROCYCLES CONTAINING A PENDANT FUNCTIONAL GROUP | BRIDGESTONE CORPORATION (JP) | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017195-A1 | PROCESS FOR FUNCTIONALIZATION OF ORGANO-ZINC COMPOUNDS WITH HALOSILANES USING BASIC NITROGEN CONTAINING HETEROCYCLES AND SILYL-FUNCTIONALIZED COMPOUNDS PREPARED THEREBY | ZRANB2, NISCH, ZKSCAN2 | ESR1 4445/4885ESR2 3906/4885NR1H2 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.